Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferripel-3 is an oral iron replacement preparation containing iron as Iron(III) hydroxide polymaltose complex (IPC). It is indicated for the prevention and treatment of anemia caused by iron deficiency. The mechanism of action involves supplying bioavailable iron, which is absorbed in the intestine and then bound to transferrin for transport to the bone marrow where it is used in hemoglobin synthesis or stored in the liver as ferritin. Clinical studies have demonstrated its efficacy in normalizing hemoglobin values and replenishing iron stores across various age groups. The product comes in both syrup and drop formulations, with each milliliter (20 drops) or 5 ml of syrup containing 50 mg elemental iron[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ferripel-3.